JP2024543016A5 - - Google Patents

Info

Publication number
JP2024543016A5
JP2024543016A5 JP2024525632A JP2024525632A JP2024543016A5 JP 2024543016 A5 JP2024543016 A5 JP 2024543016A5 JP 2024525632 A JP2024525632 A JP 2024525632A JP 2024525632 A JP2024525632 A JP 2024525632A JP 2024543016 A5 JP2024543016 A5 JP 2024543016A5
Authority
JP
Japan
Prior art keywords
alkylene
pharmaceutically acceptable
acceptable salt
alkyl
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024525632A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543016A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/078991 external-priority patent/WO2023077126A1/en
Publication of JP2024543016A publication Critical patent/JP2024543016A/ja
Publication of JP2024543016A5 publication Critical patent/JP2024543016A5/ja
Pending legal-status Critical Current

Links

JP2024525632A 2021-10-29 2022-10-31 トランス－シクロオクテンコンジュゲート Pending JP2024543016A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163273777P 2021-10-29 2021-10-29
US63/273,777 2021-10-29
PCT/US2022/078991 WO2023077126A1 (en) 2021-10-29 2022-10-31 Trans-cyclooctene conjugates

Publications (2)

Publication Number Publication Date
JP2024543016A JP2024543016A (ja) 2024-11-19
JP2024543016A5 true JP2024543016A5 (enExample) 2025-11-11

Family

ID=84463062

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024525632A Pending JP2024543016A (ja) 2021-10-29 2022-10-31 トランス－シクロオクテンコンジュゲート

Country Status (4)

Country Link
EP (1) EP4422693A1 (enExample)
JP (1) JP2024543016A (enExample)
CN (1) CN118414169A (enExample)
WO (1) WO2023077126A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024178155A1 (en) * 2023-02-21 2024-08-29 Tambo, Inc. Trans-cyclooctene conjugates
CN119638848A (zh) * 2023-09-18 2025-03-18 深圳华大生命科学研究院 Cd3抗体与荧光素酶的融合蛋白及其应用
WO2025127934A1 (en) * 2023-12-13 2025-06-19 Tagworks Pharmaceuticals B.V. Trans-cyclooctene with improved t-linker
WO2025174248A1 (en) * 2024-02-16 2025-08-21 Tagworks Pharmaceuticals B.V. Trans-cyclooctenes with "or gate" release

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR104E (enExample)
WO2012074840A2 (en) * 2010-11-22 2012-06-07 The General Hospital Corporation Compositions and methods for in vivo imaging
ES2966631T3 (es) 2013-06-19 2024-04-23 Univ California Estructuras químicas para el suministro localizado de agentes terapéuticos
CN106659796B (zh) 2014-03-14 2021-04-30 加利福尼亚大学董事会 Tco缀合物和治疗剂递送方法
WO2017044983A1 (en) 2015-09-10 2017-03-16 Shasqi, Inc. Bioorthogonal compositions
AU2018250312C1 (en) 2017-04-07 2024-08-22 Tambo, Inc. Bioorthogonal compositions
CA3099421C (en) * 2018-05-04 2025-05-06 Tagworks Pharmaceuticals B.V. COMPOUNDS INCLUDING A BINDER TO INCREASE TRANSCYCLOOCTENE STABILITY
CN110496233B (zh) * 2019-09-05 2022-07-19 复旦大学附属中山医院 一种spect显像剂及其标记前体及其制备方法、组合物和用途

Similar Documents

Publication Publication Date Title
JP2024543016A5 (enExample)
KR101772354B1 (ko) 표적화된 피롤로벤조디아제핀 접합체
JP7834721B2 (ja) 急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法
ES2900306T3 (es) Combinación que comprende un antagonista de EP4 y un inhibidor de puntos de control inmunitario
ES2582315T3 (es) Derivado de ftalazinona-cetona, método de preparación de la misma y uso farmacéutico de la misma
ES2288694T3 (es) Diaril ureas para enfermedades mediadas por el receptor del factor de crecimiento derivado de plaquetas.
ES2654143T3 (es) Inhibidores de desmetilasas de histonas
KR20250110853A (ko) Kras g12d 저해제로서 신규한 3환 화합물 및 이의 용도
ES2684120T3 (es) Combinación de un inhibidor de IAP y un taxano
JP2023550122A5 (enExample)
ES2879679T3 (es) Alcaloides de la vinca ultrapotentes: la complejidad molecular añadida altera adicionalmente la superficie de contacto dímero dímero de la tubulina
AU2021319847A1 (en) Low molecular weight protein degraders and their applications
JP2023537066A5 (enExample)
ES2825348T3 (es) Compuestos y composición farmacéutica asociados al sistema ubiquitinación-proteasoma
BR112017018706B1 (pt) Agentes citotóxicos bifuncionais contendo o farmacoforo cti, composição farmacêutica e uso dos mesmos
ES2320183T3 (es) Analogos de camptotecina y sus metodos de preparacion.
ES2686683T3 (es) Derivados de tieno-indol funcionalizados
ES2994099T3 (en) Tetrahydroisoquinoline compounds
ES2311985T3 (es) Derivados (poli)aminoacetamida de epipodofilotoxina, su procedimiento de preparacion y sus aplicaciones en la terapeutica como agentes anticancer.
RU2011108485A (ru) Новые (поли)аминоалкиламиноалкиламидные, алкилмочевинные или алкилсульфонамидные производные эпиподофиллотоксина, способ их получения и их применение в терапии в качестве противораковых средств
JP2018535995A (ja) 癌を治療するためのピリミド−ピリダジノンの使用
BRPI0609158A2 (pt) alcanamidas substituìdas heterocìclicas úteis como inibidores de renina
ES2941771T3 (es) Derivados de dihidrocromeno
KR20240132352A (ko) Swi/snf 관련, 매트릭스 연관, 염색질의 액틴 의존성 조절 인자, 서브패밀리 a, 멤버 4(smarca4)의 표적화
KR20060109871A (ko) 증식성 질병 치료용 알파, 베타-불포화 설폭시드